Valeant CEO J. Michael Pearson told the Senate Special Committee on Aging on Wednesday he and the company “made mistakes” by being “too aggressive” in price increases on certain drugs. Valeant hiked prices on several key drugs (Nitropress and Isuprel) used to treat dangerous heart conditions by 310 percent and 720 percent respectfully and nearly 3,200 percent increase on another drug Syprine that is needed to treat a life threatening illness. Read article here…..
Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.